Palo Alto Investors is an investment advisor providing money management services.
Business Model:
Revenue: $13M
Employees: 51-200
Address: 470 University Ave
City: Palo Alto
State: CA
Zip: 94301
Country: US
Palo Alto Investors is an investment advisory company that provides money management services. It also operates as a private investment firm that offers long-term investments for high-net-worth and institutional investors based on original and fundamental research. Palo Alto Investors was founded in 1989 and is based in Palo Alto, California.
Contact Phone:
+16503250772
Contact Email:
Announced Date | Company | Transaction | Money Raised |
---|---|---|---|
12/1999 | Conductus | Debt Financing | 15M |
5/2005 | SkyPilot Networks | Series C | 15M |
7/2006 | SkyPilot Networks | Venture Round | 21M |
12/2001 | SkyPilot Networks | Series B | 24.4M |
11/2007 | Ceptaris Therapeutics | Series C | 14.5M |
1/2003 | Lumend | Series D | 23.2M |
7/2012 | Alimera Sciences | Post-IPO Equity | 40M |
1/2008 | Fisker Automotive | Series B | 20M |
9/2007 | Gemfire | Venture Round | 0 |
9/2005 | Amicus Therapeutics | Series C | 55M |
5/2021 | Gilgamesh Pharmaceuticals | Series A | 0 |
6/2011 | Revance Therapeutics | Series D | 45M |
9/2006 | Amicus Therapeutics | Series D | 60M |
2/2011 | Fisker Automotive | Private Equity Round | 0 |
9/2008 | Fisker Automotive | Series C | 0 |
5/2005 | Talima Therapeutics | Series A | 1.6M |
5/2006 | Mercator MedSystems | Series A | 2.3M |
12/2007 | Revance Therapeutics | Series C | 0 |
6/2005 | Deem | Series B | 0 |
9/2014 | NewLeaf Symbiotics | Series B | 0 |
1/2001 | Labcyte | Series A | - |
7/2002 | Labcyte | Series B | 22M |
8/2011 | Ceptaris Therapeutics | Series D | 14.4M |
6/2012 | Ceptaris Therapeutics | Series D | 10M |
1/2014 | NeXeption | Series A | 21.5M |
12/2009 | Revance Therapeutics | Series D | 0 |
4/2001 | Speedera Networks | Venture Round | 0 |
11/2005 | FlowMedica | Series D | 0 |
11/2022 | Peak Bio | Post-IPO Equity | 25M |
12/2007 | Fisker Automotive | Series A | 5.5M |
6/2007 | Paracor Medical | Series D | 44M |
5/2021 | Gilgamesh Pharmaceuticals | Series A | 0 |
9/2014 | NewLeaf Symbiotics | Series B | 0 |
1/2014 | NeXeption | Series A | 0 |
7/2012 | Alimera Sciences | Post-IPO Equity | 0 |
6/2012 | Ceptaris Therapeutics | Series D | 0 |
8/2011 | Ceptaris Therapeutics | Series D | 0 |
6/2011 | Revance Therapeutics | Series D | 0 |
2/2011 | Fisker Automotive | Private Equity Round | 0 |
12/2009 | Revance Therapeutics | Series D | 0 |
9/2008 | Fisker Automotive | Series C | 0 |
Name | Price |
---|
Name | Size | Announced Date |
---|